Gina Divenuti, MD
Hematology & Oncology · Concord, NHNPI 1912958703
Payments from drug & device makers
What this record shows
This record is dominated by education: $117 of the $149 with a category attached, or 78.4%. 7 manufacturers reported payments, led by Genentech USA, Inc. at 35.8% of the total. That places this record below the midpoint for hematology & oncology clinicians in NH, where the typical reported total is $223.
Across 7 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$53
- Pfizer$21
- Merck$18
- Novocure Inc.$16
- Rigel Pharmaceuticals, Inc.$16
- Karyopharm Therapeutics Inc.$12
- plus $12 from 1 others
What the payments were for
- Food & beverage$3222%
- Education$11778%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 1 | $53 |
| Pfizer | 1 | $21 |
| Merck | 1 | $18 |
| Novocure Inc. | 1 | $16 |
| Rigel Pharmaceuticals, Inc. | 1 | $16 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
| Gilead | 1 | $12 |
How this compares
$149 in reported general payments places this provider in the 35th percentile of 61 hematology & oncology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $6,925 |
| Exemestane | 28 | $6,540 |
| Anastrozole | 193 | $3,982 |
| Tamoxifen Citrate | 56 | $1,634 |
| Letrozole | 55 | $984 |
| Potassium Chloride | 13 | $889 |
| Hydroxyurea | 43 | $575 |
| Olanzapine | 26 | $462 |
| Acyclovir | 18 | $396 |
| Dexamethasone | 35 | $333 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 14 | $155 |
| Prochlorperazine Maleate | 15 | $140 |
| Prednisone | 15 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $21 | $6,92512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 61 hematology & oncology providers in New Hampshire.
Other hematology & oncology in Concord
- Michael BuffConcord$831
- Jeanna WalshConcord$530
- Josy MathewConcord$341
- Meredith SelleckConcord$199
- Douglas WecksteinConcord$119
- Frederick BriccettiConcord$97
- Charles CatcherConcord$45
- Frederick LansiganLebanon$23K
- Parth ShahLebanon$18K
- Nancy ChunNashua$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.